Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods

作者：Yuxi Cheng, Zhengzheng Song, Juan Chen, Zhangui Tang, Baisheng Wang · 发表于：Heliyon · 年份：2024 · DOI：10.1016/j.heliyon.2024.e25895 · 被引用次数：22 · 研究领域：Cancer Immunotherapy and Biomarkers、Extracellular vesicles in disease、Peptidase Inhibition and Analysis

Oral squamous cell carcinoma (OSCC) affects a large number of individuals worldwide. Despite advancements in surgery, radiation, and chemotherapy, satisfactory outcomes have not been achieved. In recent years, the success of drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has led to breakthroughs in cancer treatment, but systematic summaries on their effectiveness against OSCC are lacking. This article reviews the latest research on the PD-1/PD-L1 pathway and the potential of combination therapy based on this pathway in OSCC. Further, it explores the mechanisms involved in the interaction of this pathway with exosomes and protein-protein interactions, and concludes with potential future OSCC therapeutic strategies.